Centrum 7/6  banner

Endo granted extended U.S. rights for Voltaren Gel

Print Friendly, PDF & Email

DUBLINIreland — Endo International plc has received an extension of its exclusive U.S. marketing rights for Voltaren Gel (diclofenac sodium topical gel 1%), a nonsteriodal anti-inflammatory drug (NSAID).

Voltaren Gel_EndoEndo said Monday that it also was granted extended U.S. rights for the product’s authorized generic, should the company choose to launch it commercially in the future.

Through an indirect subsidiary, Endo has entered into a licensing agreement with Sandoz Inc. and Novartis AG through June 30, 2023, for Voltaren Gel, which is used to alleviate joint pain from osteoarthritis in the knees, ankles, feet, elbows, wrists and hands.

Under the terms of the seven-year agreement, Endo will make additional payments as long as there is no entry of a generic competitor product and the same minimum sales royalties and tiered, double-digit royalties on net sales of Voltaren Gel in the United States as the current licensing agreement. Sandoz will continue to supply the product to Endo.

“We are very proud of Voltaren Gel’s market leading position and are therefore very pleased to extend our marketing rights and continue this successful commercialization,” stated Rajiv De Silva, president and chief executive officer of Endo. “Endo has a long-standing commitment to supporting the pain community. With this agreement, we can now continue to provide Voltaren Gel as an important product in our innovative pain product portfolio.”


Comments are closed.